EMT-related gene risk model establishment for prognosis and drug treatment efficiency prediction in hepatocellular carcinoma

被引:1
|
作者
Gao X. [1 ]
Yang C. [1 ,2 ,3 ]
Li H. [1 ,2 ,3 ,4 ]
Shao L. [1 ,2 ,4 ]
Wang M. [1 ,2 ,3 ]
Su R. [1 ]
机构
[1] The First Clinical Medical College, Gansu University of Chinese Medicine, Gansu, Lanzhou
[2] Department of Geriatrics, Affiliated Hospital of Gansu University of Chinese Medicine, Gansu, Lanzhou
[3] Key Laboratory of Traditional Chinese Herbs and Prescription Innovation and Transformation of Gansu Province and Gansu Provincial Traditional Chinese Medicine New Product Innovation Engineering Laboratory, Gansu University of Chinese Medicine, Gansu, Lanzh
[4] Key Laboratory of Dunhuang Medicine and Transformation, Ministry of Education, Gansu University of Chinese Medicine, Gansu, Lanzhou
关键词
D O I
10.1038/s41598-023-47886-z
中图分类号
学科分类号
摘要
This study was designed to evaluate the prognosis and pharmacological therapy sensitivity of epithelial mesenchymal transition-related genes (EMTRGs) that obtained from the EMTome database in hepatocellular carcinoma (HCC) using bioinformatical method. The expression status of EMTRGs were also investigated using the clinical information of HCC patients supported by TCGA database and the ICGC database to establish the TCGA cohort as the training set and the ICGC cohort as the validation set. Analyze the EMTRGs between HCC tissue and liver tissue in the TCGA cohort in the order of univariate COX regression, LASSO regression, and multivariate COX regression, and construct a risk model for EMTRGs. In addition, enrichment pathways, gene mutation status, immune infiltration, and response to drugs were also analyzed in the high-risk and low-risk groups of the TCGA cohort, and the protein expression status of EMTRGs was verified. The results showed a total of 286 differentially expressed EMTRGs in the TCGA cohort, and EZH2, S100A9, TNFRSF11B, SPINK5, and CCL21 were used for modeling. The TCGA cohort was found to have a worse outcome in the high-risk group of HCC patients, and the ICGC cohort confirmed this finding. In addition, EMTRGs risk score was shown to be an independent prognostic factor in both cohorts by univariate and multivariate COX regression. The results of GSEA analysis showed that most of the enriched pathways in the high-risk group were associated with tumor, and the pathways enriched in the low-risk group were mainly associated with metabolism. Patients in various risk groups had varying immunological conditions, and the high-risk group might benefit more from targeted treatments. To sum up, the EMTRGs risk model was developed to forecast the prognosis for HCC patients, and the model might be useful in assisting in the choice of treatment drugs for HCC patients. © 2023, The Author(s).
引用
收藏
相关论文
共 50 条
  • [41] Exploration of immune and metabolism gene signature for prognosis of esophageal carcinoma and establishment of a combined prediction model
    Wu, H.
    Luo, Y.
    Wu, G.
    Xiao, C.
    Ouyang, Z.
    Qian, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S877 - S877
  • [42] Genetic Variation in the PNPLA3 Gene and Hepatocellular Carcinoma in USA: Risk and Prognosis Prediction
    Hassan, Manal M.
    Kaseb, Ahmed
    Etzel, Carol J.
    El-Serag, Hashem
    Spitz, Margaret R.
    Chang, Ping
    Hale, Katherine S.
    Liu, Mei
    Rashid, Asif
    Shama, Mohamed
    Abbruzzese, James L.
    Loyer, Evelyne M.
    Kaur, Harmeet
    Hassabo, Hesham M.
    Vauthey, Jean-Nicolas
    Wray, Curtis J.
    Hassan, Basmah S.
    Patt, Yehuda Z.
    Hawk, Ernest
    Soliman, Khalid M.
    Li, Donghui
    MOLECULAR CARCINOGENESIS, 2013, 52 : 139 - 147
  • [43] Establishment of individual prediction model according to risk factors for development of hepatocellular carcinoma in Korea.
    Han, KH
    Youn, CJ
    Kee, KD
    Hoon, AS
    Han, PY
    Hoon, SK
    Jun, SK
    Il, S
    Yoon, CC
    Myoung, MY
    HEPATOLOGY, 2001, 34 (04) : 177A - 177A
  • [44] Establishment and validation of a novel lysosome-related gene signature for predicting prognosis and immune landscape in hepatocellular carcinoma
    Haoling Li
    Jing Li
    Xiangyu Qu
    Hengwen Dai
    Junjie Liu
    Mengxi Ma
    Jian Wang
    Wei Dong
    Wenrui Wang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 17543 - 17557
  • [45] Establishment and Validation of a Peroxisome-related Gene Signature for Prognostic Prediction and Immune Distinction in Hepatocellular Carcinoma
    Miao, Dan
    Xu, Qian
    Zeng, Yuan
    Zhao, Rui
    Song, Xian
    Chen, Zhuoyan
    Zeng, Liuwei
    Zhao, Luying
    Lin, Zhuo
    Yu, Fujun
    JOURNAL OF CANCER, 2022, 13 (05): : 1418 - 1435
  • [46] Establishment and validation of a novel lysosome-related gene signature for predicting prognosis and immune landscape in hepatocellular carcinoma
    Li, Haoling
    Li, Jing
    Qu, Xiangyu
    Dai, Hengwen
    Liu, Junjie
    Ma, Mengxi
    Wang, Jian
    Dong, Wei
    Wang, Wenrui
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (19) : 17543 - 17557
  • [47] Development of a novel tumor microenvironment-related radiogenomics model for prognosis prediction in hepatocellular carcinoma
    Wang, Yaqi
    Gao, Bin
    Xia, Chunhua
    Peng, Xiaozheng
    Liu, Haifeng
    Wu, Senlin
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2023, 13 (09) : 5803 - +
  • [48] Telomere-related gene risk model for prognosis prediction in colorectal cancer
    Chen, Hao
    Pan, Yuhao
    Lv, Chenhui
    He, Wei
    Wu, Dingting
    Xuan, Qijia
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (07)
  • [49] Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma
    Cong, Tianhao
    Luo, Yingen
    Liu, Yu
    Yang, Chao
    Yang, Hongcai
    Li, Yujie
    Li, Jingui
    Li, Xiao
    FRONTIERS IN GENETICS, 2022, 13
  • [50] A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma
    Genhao Zhang
    Lisa Su
    Xianping Lv
    Qiankun Yang
    Cancer Cell International, 21